Healthcare / BiotechnologyNasdaqGS
$12.71
-0.48 (-3.64%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-104.5M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-33.9%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-162.5M · FCF $-146.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Net Income | $-162.5M | $-162.5M | $-129.5M | $-96.7M | $-104.8M | $-71.1M | $-22.1M | $-4.3M |
| EBITDA | $-178.2M | $-178.2M | $-141.9M | $-104.6M | $-106.6M | $-71.3M | $-21.5M | $-4.3M |
| EPS | — | — | -2.20 | -2.14 | -2.62 | -1.80 | -3.42 | -1.66 |
| Balance Sheet | ||||||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | — | — | — |
| Current Ratio | 10.88 | 10.88 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-146.7M | $-146.7M | $-104.5M | $-83.7M | $-82.4M | $-52.3M | $-19.9M | — |
| Returns | ||||||||
| ROE | -33.9% | -33.9% | -31.7% | -38.1% | -53.0% | -25.0% | -6.5% | 40.7% |
| Valuation | ||||||||
| P/B | 2.16 | 2.16 | 0.85 | 2.01 | 0.58 | — | — | — |
| Growth & Yield | ||||||||
| EPS Growth | — | — | -2.8% | 18.3% | — | 47.4% | -106.0% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+140.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.20 → n/d
Residual
+140.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.